Sirtris Pharmaceuticals Presents at Cowen and Company Health Care Conference & the IBC Life Sciences Metabolic Disorders Confere
March 13 2008 - 8:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced that
it will be presenting at Cowen and Company�s 28th Annual Health
Care Conference in Boston on Tuesday, March 18 at 10:15 am EST. The
presentation will be webcast live and can be accessed on the
Sirtris website (www.sirtrispharma.com) in the "Investor Relations"
section. A replay will be available after the presentation and will
be archived on the company's website for two weeks. Sirtris will
also be presenting in Chapel Hill, North Carolina at the IBC Life
Sciences Conference titled Targeting Metabolic Disorders: Advancing
the Efficacy, Safety and Selectivity of Metabolic Disease
Therapeutics. The presentation, which is part of the
Next-Generation Diabetes Targets section, will be at 2:45 pm EST.
In January, Sirtris announced positive Phase 1b clinical trial
results with drug candidate SRT501, a proprietary formulation of
resveratrol, in patients with Type 2 Diabetes. SRT501, which
targets the SIRT1 enzyme, was found to be safe and well-tolerated,
and significantly lowered glucose at the two-hour time point in an
oral glucose tolerance test conducted as part of the 28 day Phase
1b trial of patients with Type 2 Diabetes who were naive to
treatment. Sirtris' new chemical entities (NCEs) activate SIRT1 and
are chemically distinct from and 1000 times more potent, in vitro,
than resveratrol. The NCEs have been shown to lower glucose and
improve insulin sensitivity in predictive pre-clinical models of
Type 2 Diabetes. SIRT1 activators have the potential to be
frontline therapy for Type 2 Diabetes. About Sirtris
Pharmaceuticals Sirtris Pharmaceuticals is a biopharmaceutical
company focused on discovering and developing proprietary, orally
available, small molecule drugs with the potential to treat
diseases associated with aging, including metabolic diseases such
as Type 2 Diabetes. Our drug candidates are designed to mimic
certain beneficial health effects of calorie restriction, without
requiring a change in eating habits, by activation of sirtuins, a
recently discovered class of enzymes that the Company believes
control the aging process. The company's headquarters are in
Cambridge, Massachusetts. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, the potential therapeutic effects of SIRT1
activators including NCEs for diseases of aging, such as Type 2
Diabetes: the progress and results of pre-clinical and clinical
studies of SIRT1 activators, such as SRT501 and Sirtris� NCEs; and
the potential of sirtuin modulators to receive regulatory approval.
These forward-looking statements about future expectations, plans
and prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack
of results that would provide a basis for predicting whether any of
the Company's product candidates will be safe or effective, or
receive regulatory approval, the possibility that results of
pre-clinical studies are not necessarily predictive of clinical
trial results, the Company's potential inability to initiate and
complete pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of the
Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Aug 2023 to Aug 2024